Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a commercial stage biotechnology company based in South San Francisco, California, focused on therapies for hematologic disorders and cancer. This news page aggregates company announcements, financial updates and clinical data disclosures so readers can follow Rigel’s progress across its marketed products and development pipeline.
Rigel’s news flow frequently covers net product sales and total revenue from its hematology and oncology portfolio, including TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib). Press releases detail quarterly and preliminary annual revenue, contract revenues from collaborations and government contracts, and commentary from management on commercial execution and financial performance.
Clinical and regulatory milestones are another major focus of Rigel’s news. Updates describe Phase 1b data for the investigational IRAK1/4 dual inhibitor prodrug R289 in relapsed or refractory lower-risk myelodysplastic syndrome, including safety, tolerability, pharmacokinetics and measures such as red blood cell transfusion independence. The company also reports on long-term and real-world data for REZLIDHIA in mIDH1 acute myeloid leukemia, and on presentations of pralsetinib data in RET fusion-positive solid tumors at oncology conferences.
Rigel’s releases highlight participation in scientific and investor meetings, such as the American Society of Hematology Annual Meeting and Exposition, the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium, and major healthcare investment conferences. Corporate news can also include collaboration updates, such as developments in the ocadusertib program with Eli Lilly and Company, and stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4).
Investors, clinicians and researchers can use this RIGL news feed to monitor earnings announcements, pipeline readouts, regulatory designations and conference presentations that shape the company’s trajectory in hematology and oncology.
On July 27, 2020, Rigel Pharmaceuticals (Nasdaq: RIGL) announced the publication of a post-hoc data analysis of TAVALISSE in the British Journal of Haematology. This analysis highlights a 78% response rate in adult patients with chronic immune thrombocytopenia (ITP) receiving TAVALISSE as a second-line therapy. Adverse events were manageable and consistent with previous reports. The findings suggest a potential shift in treatment paradigms, emphasizing the need for novel options in ITP management, as existing treatments are often insufficient for many patients.
Rigel Pharmaceuticals announced an investigator-sponsored trial (IST) by Imperial College London to assess the efficacy of fostamatinib, an oral SYK inhibitor, for treating COVID-19 pneumonia. Fostamatinib, marketed as TAVALISSE in the U.S., is FDA-approved for chronic immune thrombocytopenia. The trial aims to determine its effectiveness compared to ruxolitinib and standard care in preventing severe COVID-19 pneumonia. Initial studies suggest fostamatinib may inhibit inflammatory processes involved in the disease, providing hope for patients experiencing acute respiratory distress syndrome.